Head of RNA at Merck to speak at 3rd RNAi Research-Therapeutics Conference May 30-31, 2012 Boston

Boston, MA (PressExposure) April 12, 2012 -- Matthew Stanton, Head of RNA Optimization at Merck will give a featured presentation on "Recent Advances in Lipid Nanoparticle (LNP) Mediated siRNA Delivery" at the 3rd RNAi Research and Therapeutics Conference taking place on May 30-31, 2012 in Boston, MA.

Lipid nanoparticles (LNP) represent the most advanced delivery platform for siRNA therapeutics. Merck's efforts in LNP mediated siRNA delivery has focused upon optimization of the individual lipid components within the LNP (chemical SAR), optimization of the formulation parameters (compositional and process SAR) and mechanistic understanding of LNP mediated delivery. Dr. Stanton's presentation will focus on the discovery of low MW cationic lipids as a novel class of siRNA delivery agents with improved in vivo tolerability and expanded therapeutic margins.

Matthew G. Stanton is currently the head of Merck's RNA Optimization group in the Process Chemistry organization based in Rahway, NJ. He began his professional career at Merck Research Laboratories in West Point, PA in 1997 as a Staff Chemist in the Medicinal Chemistry Department. While taking a leave from Merck, he received his Ph.D. in Chemistry in 2003 from the University of North Carolina, Chapel Hill. Matt then returned to Merck, where he worked on the discovery of b-secretase inhibitors for the treatment of Alzheimer's disease. In 2004 he moved to Merck-Boston to help establish this new research center where he continued to work in the Alzheimer's disease area and ultimately led the small molecule discovery efforts targeting tau phosphorylation. In 2008 Matt moved to the RNAi Medicinal Chemistry Department in West Point, where he led the lipid nanoparticle delivery efforts until 2011.

GTC's 3rd RNAi Research and Therapeutics conference brings together the leading experts across industry and academia to discuss their findings on RNAi and cutting edge applications for drug delivery, therapeutic approaches, diagnostics, as well as target discovery and validation. Hear from key representatives in the field including Dr. Craig Mello, co-discoverer of RNAi, Dr. John J. Rossi, and research heads from industrial players such as Merck and Alnylam, who are currently pursuing RNAi in clinical or pre-clinical development.

The conference is part of the Omics Evolution Summit, which includes 6 co-located conferences. Register for the entire summit and have access to the all of the following conferences:

2nd Genomic & Proteomic Drug Discovery Conference
2nd Epigenetics in Drug Discovery Conference
7th Protein Kinases in Drug Discovery Conference
2nd Next Generation Sequencing Conference
Genome-wide Partnering and Deal Making Conference

Sign up for the pre-summit workshop on Clinical Sequencing on May 29th. This interactive workshop is dedicated to discussing emerging technologies, current and future trends of clinical sequencing, and the implementation of next generation sequencing in a CLIA environment.

For more information, please visit http://www.gtcbio.com

About GTC Conferences

GTC organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.

GTC (Global Technology Community), LLC, is a privately held company founded in 2002.

Press Release Source: http://PressExposure.com/PR/GTC_Conferences.html

Press Release Submitted On: April 12, 2012 at 1:26 am
This article has been viewed 50768 time(s).